<DOC>
	<DOCNO>NCT00660920</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose recommend dose oral AP24534 define schedule ( QD ) patient refractory advanced chronic myelogenous leukemia refractory hematologic malignancy .</brief_summary>
	<brief_title>Safety Study AP24534 Treat Chronic Myelogenous Leukemia ( CML ) Other Hematological Malignancies</brief_title>
	<detailed_description>The purpose study determine maximum tolerate dose recommend dose oral AP24534 define schedule ( QD ) patient refractory advanced chronic myelogenous leukemia refractory hematologic malignancy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Ponatinib</mesh_term>
	<criteria>Male Female ≥ 18 year old Diagnosed hematologic malignancy ( lymphoma ) relapse refractory standard care standard care available acceptable Able give write informed consent ECOG performance status ≤ 2 BSA ≥ 1.5 m² ( first cohort ) Minimum life expectancy 3 month Adequate renal function define serum creatinine &lt; 1.5× upper limit normal ( ULN ) institution Adequate hepatic function ( define : Total bilirubin &lt; 1.5 × ULN institution ; ALT AST &lt; 2.5 × ULN institution [ &lt; 5 X ULN liver involvement leukemia ] ; Prothrombin time &lt; 1.5 × ULN ) Ability comply study procedure Investigator 's opinion Adequate cardiac function define ejection fraction ( EF ) &gt; 40 % method investigator 's choice Normal QTcF interval screen ECG evaluation , define QTcF &lt; 450 ms. For female childbearing potential , negative pregnancy test must document prior enrollment Female patient childbearing potential must agree use effective form contraception sexual partner throughout participation study Have cytotoxic chemotherapy radiotherapy within 21 day prior enter study , recover adverse event due agent administer 28 day early exception alopecia Received investigational agent receive investigational agent within 14 day start ponatinib Malabsorption syndrome illness could affect oral absorption Significant uncontrolled cardiac disease Patients take medicinal product know associated prolongation QT interval electrocardiogram . Uncontrolled hypertension ( Diastolic BP &gt; 100 mmHg ; Systolic &gt; 150 mmHg ) Uncontrolled intercurrent illness Pregnant Known infection HIV Autologous allogeneic stem cell transplant &lt; 3 month prior enrollment ; evidence ongoing graft versus host disease ( GVHD ) , GVHD require immunosuppressive therapy Another primary malignancy within past 3 year Any condition illness , opinion investigator , would compromise patient safety interfere evaluation safety drug Patients take medicinal product know associated prolongation QT interval electrocardiogram Major surgery ( exception intravenous catheter placement bone marrow biopsy ) within 14 day prior initiate ponatinib therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>